Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 1.00 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.56 |
| ▸ | HSD17B3 | P37058 | 4/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003296 | 1.00 | NOTUM (1.00) | NOTUMKCNN4KCNA3HSD17B3CES1 | |
| SCHEMBL7003872 | 0.85 | NOTUM (0.73) | NOTUMKCNN4KCNA3HSD17B3CES1 | |
| SCHEMBL68594 | 0.84 | NOTUM (0.72) | NOTUMHSD17B3CYP2D6CYP2C9LMNA | |
| SCHEMBL5711999 | 0.82 | NOTUM (0.70) | NOTUMKCNN4KCNA3CES1CYP2C9 | |
| SCHEMBL642025 | 0.82 | NOTUM (0.70) | NOTUMHSD17B3CYP2D6CYP2C9LMNA | |
| SCHEMBL68111 | 0.80 | KCNN4 (0.68) | NOTUMKCNN4KCNA3LMNARAB9A | |
| SCHEMBL30667212 | 0.79 | NOTUM (0.64) | NOTUMKCNN4KCNA3LMNARAB9A | |
| SCHEMBL7004709 | 0.79 | NOTUM (0.64) | NOTUMKCNN4KCNA3LMNARAB9A | |
| SCHEMBL5712023 | 0.77 | NOTUM (0.62) | NOTUMKCNN4KCNA3HSD17B3LMNA | |
| SCHEMBL4802697 | 0.75 | HSD17B3 (0.64) | NOTUMHSD17B3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041367-B | Indolo delta-sultone compound, crystal form and preparation method thereof | 成都大学 | 2024-10-29 | — | — | CN | claimed |
| CN-113980039-B | Photothermal agent and preparation method and application thereof | 杭州师范大学 | 2023-08-18 | — | — | CN | claimed |
| CN-116041367-A | Indolo delta-sultone compound, crystal form and preparation method thereof | 成都大学 | 2023-05-02 | — | — | CN | claimed |
| CN-113980039-A | Photothermal agent and preparation method and application thereof | 杭州师范大学 | 2022-01-28 | — | — | CN | claimed |
| CN-110922350-B | N-acetyl-3-oxyindole compound and construction method of C-O bond at C2 position thereof | 贵州医科大学 | 2021-09-28 | — | — | CN | claimed |
| CN-110922350-A | N-acetyl-3-oxyindole compound and construction method of C-O bond at C2 position thereof | 贵州医科大学 | 2020-03-27 | — | — | CN | claimed |
| WO-2011068990-A1 | COMPOSITIONS AND METHODS FOR INHIBITING DYRK1A TO TREAT CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | MEDIPROPHARMA, INC. (US) | 2011-06-09 | — | — | WO | claimed |
| US-20110021776-A1 | COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | MEDIPROPHARMA, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-1432428-B1 | Agent for colouring fibres containing keratin | HENKEL KGAA (DE) | 2006-11-02 | — | — | EP | claimed |
| EP-1432428-A1 | Agent for colouring fibres containing keratin | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-06-30 | — | — | EP | claimed |
| WO-2003030842-A1 | AGENT FOR COLOURING FIBRES CONTAINING KERATIN | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-04-17 | — | — | WO | claimed |
| CN-119841845-A | Indolo delta-sultone crystal form compound and application thereof | 成都大学 | 2025-04-18 | — | — | CN | disclosed |
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| CN-116041367-B | Indolo delta-sultone compound, crystal form and preparation method thereof | 成都大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-117603121-A | C (sp) of indol-3-one 3 ) Process for preparing-H aminated derivatives | 温州医科大学 | 2024-02-27 | — | — | CN | disclosed |
| EP-0462928-A2 | Indolinimin dyes | CIBA-GEIGY AG (CH) | 1991-12-27 | — | — | EP | disclosed |
| EP-0296048-B1 | DERIVATIVES OF PIPERAZINYL ALKYL PIPERAZINE DIONE, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1991-11-21 | — | — | EP | disclosed |
| US-4943577-A | PSYCHOLOGICAL DISORDERS | ADIR ET CIE (FR) | 1990-07-24 | — | — | US | disclosed |
| US-4877788-A | ANXIOLYTIC, ANTIAGGRESSIVE OR ANTIPSYCHOTIC AGENT | ADIR ET CIE (FR) | 1989-10-31 | — | — | US | disclosed |
| EP-0296048-A1 | Derivatives of piperazinyl alkyl piperazine dione, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1988-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | NOTUM 4253/4885KCNN4 4564/4885KCNA3 3539/4885 |
| US-20110021776-A1 | COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PYGB, NLN, INA | NOTUM 2480/4885KCNN4 2382/4885KCNA3 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.